Summary & Overview
HCPCS Level II Q4177: Floweramnioflo, 0.1 cc
HCPCS Level II code Q4177 represents a 0.1 cc unit of Floweramnioflo, a small-volume biologic or therapeutic product. Nationally, HCPCS Level II products classified under Q-series codes are used by payers and providers to identify non-physician supplies and drugs that are typically billed separately from procedural codes. Clear identification of such product units matters for accurate billing, inventory control, and payer adjudication across outpatient and ambulatory settings.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical and billing context, typical sites of service, common modifiers used with HCPCS Level II items, and the types of benchmarks and policy considerations that affect coverage and reimbursement for small-volume biologic products. The publication explains how the code is used in claims, the operational implications for supply chain and clinical administration, and where stakeholders should look for payer-specific guidance or edits. Data not available in the input will be clearly noted where applicable.
Billing Code Overview
HCPCS Level II code Q4177 describes Floweramnioflo, 0.1 cc. The service represents a small-volume biological or therapeutic product prepared in a 0.1 cc unit.
-
Service type: Product administration / biologic product dose
-
Typical site of service: Ambulatory clinics, outpatient infusion or procedure rooms, and hospital outpatient departments where small-volume biologic products are administered or supplied
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a pregnant woman presenting for targeted intra-amniotic therapy or diagnostic testing where a small-volume amniotic fluid preparation, Q4177 (Floweramnioflo, 0.1 cc), is administered or utilized. The clinical workflow begins in a maternal–fetal medicine clinic or outpatient obstetrics setting: the indication may include facilitation of laboratory assays, adjunctive intra-amniotic medication delivery, or use as a specimen/control for specialized testing. The patient undergoes counseling and informed consent, ultrasound-guided amniocentesis or transabdominal access as appropriate, sterile preparation, and collection or instillation of small-volume amniotic product. Monitoring for maternal and fetal well-being follows the procedure, with observation for complications such as uterine activity, bleeding, infection, or fetal distress. Typical site of service is an outpatient obstetrics or maternal–fetal medicine clinic, ambulatory surgical center, or hospital outpatient department depending on procedure complexity and patient comorbidities.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no specific modifier applies to the service. |
22 |